

# Recombinant Human Interleukin 4 (IL-4)

Catalog Number PHC0044 (10 µg), PHC0045 (25 µg), PHC0041 (100 µg), PHC0043 (1 mg)

Pub. No. MAN0003621 Rev. 3.0

## Product specifications

<b>Lot number</b>	See product label.
<b>Molecular weight</b>	14.9 kDa
<b>Purity</b>	>95% as determined by SDS PAGE analysis.
<b>Amino acid sequence</b>	HKCDITLQEI IKTLNSLSEQ KTLCTELTVT DIFAASKNTT EKETFCRAAT VLRQFYSHHE KDTRCLGATA QQFHRHKQLI RFLKRLDRNL WGLAGLNSCP VKEANQSTLE NFLERLKTIM REKYSKCSS
<b>Biological activity</b>	ED <sub>50</sub> 0.05–0.4 ng/mL (specific activity: 2.0 x 10 <sup>7</sup> to 2.5 x 10 <sup>6</sup> units/mg), determined by measuring the dose dependent proliferation of human TF-1 cells. Determine the optimal concentration for each specific application using an initial dose response assay (a concentration range of 0.1–10.0 ng/mL is effective for most <i>in vitro</i> applications).
<b>Formulation</b>	Lyophilized, carrier free.
<b>Sterility</b>	Filtered before lyophilization through a 0.22 micron sterile filter.
<b>Endotoxin</b>	<0.1 ng/µg
<b>Production</b>	Produced in <i>E. coli</i> and purified via sequential chromatography.
<b>Reconstitution recommendation</b>	Centrifuge the vial briefly, before opening to bring the contents to the bottom. Reconstitute the lyophilized protein in sterile, deionized water to 0.1–1.0 mg/mL to regain full activity. Apportion the reconstituted protein into working aliquots and store at ≤ –20°C. Make any further dilutions of the reconstituted protein in low endotoxin medium or buffered solution with FCS or tissue culture grade BSA.
<b>Suggested working dilutions</b>	The optimal concentration should be determined for each specific application.
<b>Storage</b>	Store the lyophilized protein at 2–8°C, preferably desiccated. Upon reconstitution, apportion into working aliquots and store at ≤ –20°C (not in a frost-free freezer). Avoid repeated freeze-thaw cycles.
<b>Expiration date</b>	Expires one year from date of receipt when stored as instructed.
<b>References</b>	<p>Paul, WE. (1991) Interleukin 4: A prototypical immunoregulatory lymphokine. <i>Blood</i> 77:1859-1870.</p> <p>Chapoval, AI, Tamada, K, and Chen, LP. (2000). In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. <i>Blood</i> 95(7):2346-2351.</p> <p>Francisco, JA, Donaldson, KL, Chace, D, Siegall, CB, and Wahl, AF. (2000) Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. <i>Cancer Research</i> 60(12):3225-3231.</p> <p>Gubina, E, Luo, X, Kwon, E, Sakamoto, K, Shi, YF, and Mufson, RA. (2001) B c cytokine receptor-induced stimulation of cAMP response element binding protein phosphorylation requires protein kinase C in myeloid cells: A novel cytokine signal transduction cascade. <i>J. Immunol.</i> 167(8):4303-4310.</p> <p>Kahlert, H, Grage-Griebenow, E, Stuwe, HT, Cromwell, O, and Fiebig, H. (2000) T cell reactivity with allergoids: Influence of the type of APC. <i>J. Immunol.</i> 165(4):1807-1815.</p> <p>Kim, DK, Lee, TV, Catilleja, A, Anderson, BW, Peoples, GE, Kudelka, AP, Murray, JL, Sittisomwong, T, Wharton, JT, Kim, JW and Ioannides, CG. (1999) Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. <i>Anticancer Research</i> 19:2907-2916.</p> <p>Parada, NA, Center, DM, Kornfeld, H, Rodriguez, WL, Cook, J, Vallen, M, and Cruikshank, WW. (1998) Synergistic activation of CD4+ T cells by IL-16 and IL-2. <i>J. Immunol.</i> 160(5):2115-2120.</p> <p>Piccinini, G, Foli, A, Comolli, G, Lisziewicz, J, and Lori, F. (2002) Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. <i>J. Virol.</i> 76 (5): 2274-2278.</p> <p>Rao, RM, Haskard, DO, and Landis, RC. (2002) Enhanced recruitment of TH2 and CLA-Negative lymphocytes by the S128R polymorphism of E-Selectin(1). <i>J. Immunol.</i> 169 (10):5860-5865.</p>

<b>References</b> , continued	<p>Voburka, Z, Vetvicka, V, Vetvickova, J, and Fusek, M. (2002) Cytokines affect procathepsin D-stimulated proliferation of breast cancer cells. <i>Anticancer Res.</i> 22(2A):913-919.</p> <p>Wagers, AJ, Waters, CM, Stoolman, LM, and Kansas, GS. (1998) Interleukin 12 and interleukin 4 control T cell adhesion to endothelial selectins through opposite effects on alpha1,3-fucosyltransferase VII gene expression. <i>J. Exp. Med.</i> 188(12):2225-2231.</p> <p>Wang, HS, Cao, HJ, Winn, VD, Rezanka, LJ, Frobert, Y, Evans, CH, Sciaky, D, Young, DA, and Smith, TJ. (1996) Leukoregulin induction of prostaglandin-endoperoxide H synthase-2 in human orbital fibroblasts. An in vitro model for connective tissue inflammation. <i>J. Biol. Chem.</i> 271(37):22718-22728.</p> <p>Yu, Y, Hagihara, M, Ando, K, Gansuud, B, Matsuzawa, H, Tsuchiya, T, Ueda, Y, Inoue, H, Hotta, T, and Kato, S. (2001) Enhancement of human cord blood CD34(+) cell-derived NK cell cytotoxicity by dendritic cells. <i>J. Immunol.</i> 166(3): 1590-1600.</p>
-------------------------------	--

## Limited product warranty

Life Technologies Corporation and/or its affiliate(s) warrant their products as set forth in the Life Technologies' General Terms and Conditions of Sale found on Life Technologies' website at [www.thermofisher.com/us/en/home/global/terms-and-conditions.html](http://www.thermofisher.com/us/en/home/global/terms-and-conditions.html). If you have any questions, please contact Life Technologies at [www.thermofisher.com/support](http://www.thermofisher.com/support).

## Explanation of Symbols

Symbol	Description	Symbol	Description	Symbol	Description
	Manufacturer		Catalog number		Batch code
	Use by		Temperature limitation		
	Consult instructions for use		Caution, consult accompanying documents		

**Manufacturer's address:** Life Technologies Corporation | 5781 Van Allen Way | Carlsbad, CA 92008

The information in this guide is subject to change without notice.

**DISCLAIMER:** TO THE EXTENT ALLOWED BY LAW, LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) WILL NOT BE LIABLE FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING YOUR USE OF IT.

**Important Licensing Information:** This product may be covered by one or more Limited Use Label Licenses. By use of this product, you accept the terms and conditions of all applicable Limited Use Label Licenses.

©2017 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.